Intelligence Feed event · Policy · 2026-10-01

    Theriva Biologics Publishes Positive VIRAGE Phase 2b Data in Nature Medicine

    Question

    Theriva Biologics Publishes Positive VIRAGE Phase 2b Data in Nature Medicine

    Direct answer

    Theriva Biologics has published full clinical data from its Phase 2b VIRAGE trial in Nature Medicine, demonstrating that its lead candidate VCN-01, administered alongside standard chemotherapy, achieved improvements in overall survival and progression-free survival in metastatic pancreatic adenocarcinoma. The publication provides peer-reviewed validation for the viral immunotherapy platform, supporting potential progression into registrational clinical pathways.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Theriva Biologics Publishes Positive VIRAGE Phase 2b Data in Nature Medicine”, revision 1, evidence through 2026-10-01. https://marketontology.com/market-events/2026-10-01/theriva-biologics-publishes-positive-virage-phase-2b-data-in-nature-medicine-5d5720

    POLICY
    Theriva Biologics Publishes Positive VIRAGE Phase 2b Data in Nature Medicine
    Theriva Biologics has published full clinical data from its Phase 2b VIRAGE trial in Nature Medicine, demonstrating that its lead candidate VCN-01, administered alongside standard chemotherapy, achieved improvements in overall survival and progression-free survival in metastatic pancreatic adenocarcinoma. The publication provides peer-reviewed validation for the viral immunotherapy platform, supporting potential progression into registrational clinical pathways.
    TOVX
    Impact
    68
    OCT 1
    SIG
    86%
    TOVX
    Theriva Biologics Publishes Positive VIRAGE Phase 2b Data in Nature Medicine
    Theriva Biologics has published full clinical data from its Phase 2b VIRAGE trial in Nature Medicine, demonstrating that its lead candidate VCN-01, administered alongside standard chemotherapy, achieved improvements in overall survival and progression-free survival in metastatic pancreatic adenocarcinoma. The publication provides peer-reviewed validation for the viral immunotherapy platform, supporting potential progression into registrational clinical pathways.
    → Peer-reviewed Phase 2b clinical validation in Nature Medicine increases the probability of regulatory advancement and partnership value for TOVX.
    Impact
    Theriva Biologics has published full clinical data from its Phase 2b VIRAGE trial in Nature Medicine, demonstrating that its lead candidate VCN-01, administered alongside standard chemotherapy, achieved improvements in overall survival and progression-free survival in metastatic pancreatic adenocarcinoma. The publication provides peer-reviewed validation for the viral immunotherapy platform, supporting potential progression into registrational clinical pathways.
    Affected
    TOVX
    Transmission
    Peer-reviewed Phase 2b clinical validation in Nature Medicine increases the probability of regulatory advancement and partnership value for TOVX.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    TOVXbiotech pipeline derisking via peer-reviewed Phase 2b clinical publicationUp1-5dNature Medicine publication confirmed survival improvements for VCN-01 in pancreatic cancer.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month